false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Too Much or Too Little? Individualizing GFR Assess ...
Too Much or Too Little? Individualizing GFR Assessments and Multidisciplinary Dose Adjustment of Anticancer Therapies in Patients with CKD and ESKD
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speakers discussed how kidney-function estimates affect anticancer drug dosing. In patients with cancer, sarcopenia can make creatinine-based eGFR falsely high, increasing the risk of drug toxicity. Cystatin C can improve estimates when combined with creatinine, although it too has limitations, including effects from obesity, inflammation, smoking, corticosteroids, and some cancers. For high-stakes decisions—such as chemotherapy dosing or clinical-trial eligibility—measured GFR is preferred when available.<br /><br />The speakers also emphasized that standardized eGFR (reported per 1.73 m²) and body-surface-area-adjusted eGFR are not interchangeable. Drug clearance relates to an individual’s GFR, so choosing the appropriate measure can materially change dosing, especially for carboplatin. They advocated for individualized assessment, multidisciplinary collaboration, and adaptive rather than fixed dosing.<br /><br />During discussion, a participant stressed that estimating equations remain imprecise for individuals, particularly in people who are obese but sarcopenic, and argued for broader use of measured GFR rather than relying on eGFR for drug dosing. The speakers agreed that measured GFR is most useful in high-risk cases, while combined creatinine–cystatin C estimates can guide decisions when direct measurement is unavailable.
Asset Caption
Paul Hanna, MD, MSc, FASN; Thomas D. Nolin, PharmD, PhD, FASN
Meta Tag
Speaker
Paul Hanna
Speaker
Thomas D. Nolin
Keywords
kidney function
anticancer drug dosing
creatinine-based eGFR
cystatin C
measured GFR
chemotherapy dosing
carboplatin
×
Please select your language
1
English